Skip to content

Comorbidity and mimics

TL;DR — Persistent symptoms do not automatically mean persistent bronchoconstriction. Rhinitis/sinus disease, obesity, sleep apnea, reflux, anxiety, bronchiectasis and medication toxicity can worsen the lived asthma burden, while inducible laryngeal obstruction (ILO), dysfunctional breathing, COPD, heart disease and structural airway disease can imitate asthma or coexist with it. The safest sequence is to reconfirm variable airflow, characterize each symptom, and test plausible alternatives before escalating steroids. Objectively defined laryngeal dysfunction occurs in an estimated 25% of adults with asthma referred into heterogeneous studies, while asthma with bronchiectasis carries lower FEV1/FVC and about 0.68 more exacerbations per year in pooled observational data (Lee 2020, PMID 31940470; Zhang 2021, PMID 33530179). Treat a comorbidity for its own indication; evidence that this will improve asthma is often weaker.

A symptom-based reset

Reported problem Asthma-compatible pattern Alternative clues
“Wheeze” Expiratory, diffuse, variable, bronchodilator-responsive Inspiratory neck noise, focal monophonic sound, upper-airway rattle
Breathlessness Episodic with variable expiratory limitation Abrupt exercise onset/offset, paresthesia, cardiac signs, deconditioning
Cough Variable, nocturnal/triggered, with hyperresponsiveness Chronic wet cough, ACE inhibitor, aspiration, focal infection
Chest tightness Tracks airflow or triggers Panic/hyperventilation, ischemia, musculoskeletal pain
Night waking Asthma symptoms and reliever response Snoring/apneas, reflux, heart failure, nasal obstruction
“Treatment failure” Objective airflow/inflammation persists Empty device, technique error, wrong diagnosis, nonadherence

Comorbidity is not merely a list of diagnoses. It can be causal, share upstream risk, modify symptom perception, reduce treatment delivery or arise from treatment.

Upper airway disease

Allergic rhinitis, chronic rhinosinusitis and nasal polyps commonly coexist with asthma. In a meta-analysis anchored to non-asthma populations, allergic rhinitis had one of the strongest associations with asthma, OR 4.24 (95% CI 3.82–4.71) (Rogliani 2023, PMID 36889783).

Ask about obstruction, itch/sneeze, discharge, smell loss, facial pressure and seasonal/occupational patterns. Examine the nose when possible. The diagnosis of chronic rhinosinusitis requires a sustained compatible syndrome plus objective evidence rather than facial pain alone.

Condition Treatment target Asthma inference
Allergic rhinitis Intranasal therapy, allergen strategy, selected immunotherapy Better nasal control may improve overall airway burden
CRSwNP Intranasal corticosteroid, saline, surgery/biologic when indicated Signals type-2 disease and may inform biologic choice
AERD/N-ERD NSAID reaction history, polyps, eosinophilic asthma Avoid culprit COX-1 inhibitors; specialist pathway
Occupational rhinitis Exposure-linked nasal symptoms May precede or accompany occupational asthma

ARIA provides an integrated upper/lower-airway framework but medication choices still depend on symptom pattern and local availability (Bousquet 2020, PMID 31627910).

Endoscopic sinus surgery observational studies reported improved asthma control in 76.1% (95% CI 71.9–80.3) and fewer attacks in 84.8% (76.6–93.0), but uncontrolled before/after designs, concurrent treatment and reporting bias preclude causal estimates (Vashishta 2013, PMID 23818462).

For severe CRSwNP, omalizumab improved polyp and congestion scores in two placebo-controlled phase 3 trials; the treatment indication is sinonasal disease with relevant phenotype, not “asthma symptoms” alone (Gevaert 2020, PMID 32524991).

Obesity and deconditioning

Obesity can reduce expiratory reserve volume, amplify dyspnea, worsen reflux and sleep apnea, alter inflammation and complicate spirometric interpretation. Abdominal obesity is associated with asthma in pooled observational evidence, but association does not establish one causal phenotype (Jiang 2019, PMID 30949213).

Distinguish:

  • asthma activity: variable obstruction, attacks and airway inflammation;
  • mechanical load: breathlessness, low lung volumes and exercise limitation;
  • deconditioning: early ventilatory demand without airflow change;
  • obesity-associated comorbidities: OSA, reflux, cardiovascular and metabolic disease.

Weight-management RCTs are small and heterogeneous. A systematic review found that 5–10% weight loss was often associated with clinically meaningful asthma improvement in adults, while pediatric results suggested improved quality of life/control but inconsistent lung function (Okoniewski 2019, PMID 30605347).

A behavioral weight-loss RCT in adults did not show a universal control benefit, illustrating that weight change is not an asthma drug and that phenotype, achieved loss and intervention intensity matter (Ma 2015, PMID 25496399). Weight care should be respectful, evidence-based and justified for whole-person health.

Obstructive sleep apnea

Clues include loud snoring, witnessed apneas, unrefreshing sleep, morning headache, daytime sleepiness and resistant hypertension; children may present with behavior or learning problems.

Adult asthma populations had pooled OSA prevalence of 49.5% (95% CI 36.4–62.6) and 2.64-fold higher odds than non-asthma comparators, but referral selection and heterogeneous testing inflate uncertainty (Kong 2017, PMID 28642543).

Treat OSA to improve sleep, oxygenation and cardiovascular risk. Observational signals suggest asthma improvement after CPAP or adenotonsillectomy, but large randomized asthma-outcome trials are limited (PMID 28042927; Kohli 2016, PMID 27729114).

Gastroesophageal reflux

Reflux can coexist with asthma and contribute to cough, laryngeal symptoms or sleep disturbance. The causal relationship is bidirectional and often over-assumed. A meta-analysis of 32 studies and 1,612,361 patients found only a weak association with exacerbation, OR 1.27 (95% CI 1.18–1.35) (Mallah 2022, PMID 34448255).

Treat troublesome heartburn/regurgitation and objectively evaluate alarm symptoms. Do not prescribe acid suppression solely for poorly controlled asthma without reflux evidence.

In adults with poorly controlled asthma and little/no reflux symptomatology, esomeprazole did not improve asthma control despite frequent pH-probe reflux (PMID 19357404). In 306 children without overt reflux symptoms, lansoprazole did not improve asthma control and increased respiratory infections and other adverse events (PMID 22274684).

Inducible laryngeal obstruction

ILO is inappropriate episodic laryngeal narrowing, often inspiratory. It may mimic asthma, coexist with it, or be provoked by exercise, irritants and stress.

Feature ILO more likely Asthma more likely
Sound Inspiratory stridor/noise at neck Expiratory polyphonic chest wheeze
Exercise timing Peaks during exercise; resolves quickly after stopping Often peaks after sustained exercise
Sensation Throat closure, voice change Chest tightness
Reliever response Limited/inconsistent Reproducible when bronchoconstriction present
Confirmation Laryngoscopy during symptoms/provocation Variable expiratory airflow/hyperresponsiveness

Objectively defined laryngeal dysfunction had pooled prevalence 25% (95% CI 15–37%) in 21 asthma studies, with I² 96% and strong dependence on the diagnostic method (Lee 2020, PMID 31940470).

Because ILO is intermittent, resting laryngoscopy can be normal. Continuous laryngoscopy during exercise is useful for exercise-induced symptoms. Conventional confirmation is inspiratory vocal-fold narrowing above 50% during symptoms, while nomenclature and thresholds continue to evolve (Leong 2023, PMID 37221142).

Abrupt inspiratory symptoms, throat discomfort and rapid resolution are clues, but fiberoptic visualization during symptoms remains the reference test (Fretzayas 2017, PMID 29066919). Management typically includes explanation, trigger work and specialist speech-language/breathing retraining; acute severe distress still requires assessment for anaphylaxis and asthma.

Dysfunctional breathing

Breathing-pattern disorder can cause air hunger, sighing, chest discomfort, dizziness and tingling with normal oxygenation and absent variable obstruction. It can be driven by learned pattern, anxiety, pain, deconditioning or disease-related hypervigilance.

ILO and breathing-pattern disorder may overlap but should not be collapsed into one diagnosis. Evidence in children is less developed, and both become more recognized in adolescence (Connett 2018, PMID 30627527).

Questionnaires can screen symptoms but cannot prove mechanism. A positive hyperventilation questionnaire in a person with asthma may measure uncontrolled asthma itself. Physiotherapy assessment should be linked to objective respiratory evaluation.

Anxiety, depression and symptom perception

Anxiety is more common in asthma across observational studies, with wide variation in instruments and populations (Ye 2021, PMID 33431086). Panic can imitate attacks; attacks can cause panic; and both can occur simultaneously.

Avoid psychologizing unexplained breathlessness before assessing oxygenation and airflow. Once immediate danger is excluded, screen and treat mental-health conditions for their own burden and incorporate coping strategies into the action plan.

Bronchiectasis and chronic infection

Suspect bronchiectasis with chronic productive cough, recurrent bacterial infection, hemoptysis, crackles, digital clubbing or unexpectedly severe/fixed obstruction. Confirm with appropriate thin-section CT after weighing radiation and pretest probability.

Five observational studies found CT-defined bronchiectasis in 36.6% of 839 selected asthma patients. Comorbidity was associated with FEV1/FVC lower by 2.71 percentage points (95% CI −3.72 to −1.69) and 0.68 more exacerbations/year (0.03–1.33); selection into severe cohorts limits prevalence generalizability (Zhang 2021, PMID 33530179).

Search for allergic bronchopulmonary aspergillosis, immunodeficiency, aspiration and ciliary disease when indicated. Treat infection and airway clearance separately from asthma inflammation.

COPD and fixed airflow obstruction

Asthma and COPD are distinct syndromes that can coexist. A smoking/exposure history and persistent post-bronchodilator obstruction increase COPD probability; childhood symptoms, marked variability and type-2 features support asthma but are not exclusive.

Avoid using “overlap” as a substitute for diagnostic work. Document the evidence for each component. An asthma history generally argues against bronchodilator-only treatment without ICS, while COPD features affect bronchodilator, rehabilitation, infection and imaging decisions.

Other important alternatives

Alternative Clues Confirmation direction
Heart failure/ischemia Orthopnea, edema, exertional pressure, crackles ECG, natriuretic peptide/imaging as appropriate
Pulmonary embolism Abrupt dyspnea, pleuritic pain, risk context Urgent probability-based pathway
Foreign body Sudden onset, unilateral signs Urgent imaging/bronchoscopy pathway
Central airway lesion Fixed/monophonic wheeze, flow-volume plateau Imaging and bronchoscopy
Cystic fibrosis/PCD Wet cough, infections, sinus/ear disease, growth issues Disease-specific testing
EGPA Adult-onset asthma, eosinophilia, neuropathy, rash/systemic disease Urgent multisystem evaluation
Anaphylaxis Acute multisystem reaction, hypotension, urticaria/angioedema Immediate epinephrine-based emergency care

Pediatric difficult asthma particularly requires exclusion of cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, malacia and vascular/airway malformation (Ullmann 2018, PMID 30338252).

Repeated oral corticosteroids can cause osteoporosis, diabetes, hypertension, cataract, infection, adrenal suppression and mood effects. Pooled observational evidence associated OCS exposure in asthma with osteoporosis, HR 1.76 (95% CI 1.48–2.09), while the ICS bone-density signal was not significant in meta-analysis (Chalitsios 2021, PMID 33799052).

Medication reconciliation should also identify beta-blockers, NSAIDs in susceptible disease, sedatives worsening sleep apnea, ACE inhibitors causing cough and CYP3A4 inhibitors increasing steroid exposure.

A practical difficult-asthma sequence

  1. Verify the symptom and immediate safety.
  2. Reconfirm objective asthma evidence.
  3. Observe inhaler technique and obtain objective adherence evidence.
  4. Map each remaining symptom to plausible asthma, comorbidity or mimic mechanisms.
  5. Test only hypotheses with a reasonable pretest probability.
  6. Treat confirmed conditions for defined outcomes.
  7. Re-measure symptoms, attacks, airflow and steroid burden before escalation.

Multidimensional severe-asthma assessment improves identification of modifiable traits, but intervention packages and outcome definitions vary (Clark 2017, PMID 28776330).

Open questions

  • Which comorbidity interventions reduce severe asthma attacks in randomized trials rather than only symptom scores?
  • How should ILO be screened efficiently without overdiagnosis when provoked laryngoscopy is scarce? (Lee 2020, PMID 31940470)
  • Which obesity-associated asthma subgroups benefit most from specific metabolic or weight interventions?
  • Can combined laryngeal, cardiopulmonary exercise and airflow testing shorten diagnostic delay?
  • When does bronchiectasis represent asthma consequence, shared cause or diagnostic replacement? (Zhang 2021, PMID 33530179)

References

  1. Rogliani P, et al. Strength of association between comorbidities and asthma: meta-analysis. Eur Respir Rev. 2023. PMID 36889783
  2. Bousquet J, et al. Next-generation ARIA guidelines. J Allergy Clin Immunol. 2020. PMID 31627910
  3. Vashishta R, et al. Asthma outcomes after endoscopic sinus surgery: systematic review and meta-analysis. Int Forum Allergy Rhinol. 2013. PMID 23818462
  4. Gevaert P, et al. Omalizumab in nasal polyposis: two randomized phase 3 trials. J Allergy Clin Immunol. 2020. PMID 32524991
  5. Jiang D, et al. Association between abdominal obesity and asthma: meta-analysis. Allergy Asthma Clin Immunol. 2019. PMID 30949213
  6. Okoniewski W, et al. Weight loss for children and adults with obesity and asthma: systematic review. Ann Am Thorac Soc. 2019. PMID 30605347
  7. Ma J, et al. Behavioral weight loss and physical activity intervention in obese adults with asthma. Ann Am Thorac Soc. 2015. PMID 25496399
  8. Kong DL, et al. Association of obstructive sleep apnea with asthma: meta-analysis. Sci Rep. 2017. PMID 28642543
  9. Abdul Razak MR, et al. Obstructive sleep apnea and asthma. Asian Pac J Allergy Immunol. 2016. PMID 28042927
  10. Kohli N, et al. Asthma outcomes after adenotonsillectomy: systematic review. Int J Pediatr Otorhinolaryngol. 2016. PMID 27729114
  11. Mallah N, et al. Gastroesophageal reflux disease and asthma exacerbation: meta-analysis. Pediatr Allergy Immunol. 2022. PMID 34448255
  12. American Lung Association Asthma Clinical Research Centers. Esomeprazole for poorly controlled asthma. N Engl J Med. 2009. PMID 19357404
  13. Writing Committee for the American Lung Association Asthma Clinical Research Centers, et al. Lansoprazole for children with poorly controlled asthma: a randomized controlled trial. JAMA. 2012. PMID 22274684
  14. Lee JH, et al. Comorbid laryngeal dysfunction in asthma: systematic review and meta-analysis. J Allergy Clin Immunol. 2020. PMID 31940470
  15. Leong P, et al. Vocal cord dysfunction/inducible laryngeal obstruction: Melbourne Roundtable. Respirology. 2023. PMID 37221142
  16. Fretzayas A, et al. Differentiating vocal cord dysfunction from asthma. J Asthma Allergy. 2017. PMID 29066919
  17. Connett GJ, Thomas M. Dysfunctional breathing in children and adults with asthma. Front Pediatr. 2018. PMID 30627527
  18. Ye G, et al. Anxiety in asthma: systematic review and meta-analysis. Psychol Med. 2021. PMID 33431086
  19. Zhang SQ, et al. Asthma with comorbid bronchiectasis: systematic review and meta-analysis. Medicine. 2021. PMID 33530179
  20. Ullmann N, et al. Asthma: differential diagnosis and comorbidities. Front Pediatr. 2018. PMID 30338252
  21. Chalitsios CV, et al. Corticosteroids and bone health in asthma: systematic review and meta-analysis. Respir Med. 2021. PMID 33799052
  22. Clark VL, et al. Multidimensional assessment of severe asthma: systematic review and meta-analysis. Respirology. 2017. PMID 28776330
  23. Ledford DK, Lockey RF. Asthma and comorbidities. Curr Opin Allergy Clin Immunol. 2013. PMID 23222157
  24. Garcia-Rio F, et al. Obesity and asthma: key clinical questions. J Investig Allergol Clin Immunol. 2019. PMID 30222113
  25. Kocks JWH, et al. Critical inhaler errors and health outcomes. NPJ Prim Care Respir Med. 2018. PMID 30446655
  26. Usmani OS, et al. Critical inhaler errors: systematic review. Respir Res. 2018. PMID 29338792